title: Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
abstract: We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.
authors.affiliation: Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust, Kings College London, London, UK.
authors.forename: W
authors.initials: W
authors.lastname: Nagi
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Lim
authors.forename: P
authors.initials: P
authors.lastname: Krishnamurthy
authors.forename: V
authors.initials: V
authors.lastname: Potter
authors.forename: V
authors.initials: V
authors.lastname: Tindell
authors.forename: L
authors.initials: L
authors.lastname: Reiff-Zall
authors.forename: A
authors.initials: A
authors.lastname: Abdullah
authors.forename: N
authors.initials: N
authors.lastname: Lea
authors.forename: M
authors.initials: M
authors.lastname: Kenyon
authors.forename: J
authors.initials: J
authors.lastname: Marsh
authors.forename: A Y L
authors.initials: AY
authors.lastname: Ho
authors.forename: G J
authors.initials: GJ
authors.lastname: Mufti
authors.forename: A
authors.initials: A
authors.lastname: Pagliuca
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D055728:Primary Myelofibrosis / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine